$2 Billion Towards a Coronavirus Vaccine

381

John Trizzino, ’81, serves as Executive Vice President at Novavax, a global biotechnology company that has collectively earned over $2 billion in funding to support development of a COVID-19 vaccine. The U.S. government will pay Novavax $1.6 billion to develop a coronavirus vaccine as part of its Operation Warp Speed program, in addition to a Department of Defense (DoD) investment of up to $60 million of funding. Additionally, the Coalition for Epidemic Preparedness Innovations, a global partnership founded by Bill and Melinda Gates, awarded Novavax its largest-ever investment of a grant worth up to $388 million.